Change Language

Select Language

COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.

Diffuse Large B-cell Lymphoma (DLBCL) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2022-2032

Report Description

Diffuse Large B-cell Lymphoma (DLBCL) market is currently driven by factors such as a rising patient pool, improving diagnosis and drug treatment rates, an increase in the geriatric population and rising safety and efficacy of current and emerging therapies, etc. Diffuse Large B-Cell Lymphoma, a form of non-Hodgkin lymphoma, represents the most common blood cancer. Lymphomas develop when immune cells, known as B lymphocytes, grow and multiply in an uncontrolled way. DLBCL develops mostly in adults and is a rapidly-growing (aggressive) lymphoma. It can begin in the lymph nodes or outside of the lymphatic system in the gastrointestinal tract, testes, thyroid, skin, breast, bone, or brain. Usually, the first symptoms of DLBCL is a painless swelling in the neck, armpit, abdomen, or groin caused by enlarged lymph nodes. This swelling can also be painful for some people. Other symptoms of  DLBCL  may include night sweats, unexplained fevers, and a loss in weight. DLBCL can occur at any age, however, it is generally rare in children and is more common in older people. Most people diagnosed with DLBCL are usually 60 or over. Furthermore, DLBCL affects slightly more males than females. Other risk factors include family history, certain infections, weakened immune system, obesity, exposure to certain chemicals, etc.

IMARC Group’s new report "Diffuse Large B-cell Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast" provides an exhaustive analysis of the Diffuse Large B-cell Lymphoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The report provides an in-depth understanding of current and future landscape of the Diffuse Large B-cell Lymphoma market. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Diffuse Large B-cell Lymphoma across the seven major markets. According to the report the United States has the largest patient pool for Diffuse Large B-cell Lymphoma and also represents the largest market for Diffuse Large B-cell Lymphoma treatment. Furthermore, the current Diffuse Large B-cell Lymphoma treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Diffuse Large B-cell Lymphoma market in any manner.

Time Period of the Study

  • Base Year: 2021
  • Historical Period: 2017-2021
  • Market Forecast: 2022-2032
     

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan
     

Analysis Covered Across Each Country

  • Historical, Current and Future Epidemiology Scenario
  • Historical, Current and Future Performance of the Diffuse Large B-cell Lymphoma Market
  • Historical, Current and Future Performance of Various Therapeutic Categories in the Diffuse Large B-cell Lymphoma Market
  • Sales of Various Drugs Across the Diffuse Large B-cell Lymphoma Market
  • Reimbursement Scenario in the Diffuse Large B-cell Lymphoma Market
     

Diffuse Large B-cell Lymphoma: In-Market and Pipeline Drugs

This  report also provides a detailed analysis of the current Diffuse Large B-cell Lymphoma marketed drugs and late-stage pipeline drugs.

  • In-Market Diffuse Large B-cell Lymphoma Drugs
    • Drug Overview
    • Mechanism of Action
    • Regulatory Status
    • Clinical Trial Results
    • Drug Uptake and Market Performance
  • Late-Stage Pipeline Diffuse Large B-cell Lymphoma Drugs
    • Drug Overview
    • Mechanism of Action
    • Regulatory Status
    • Clinical Trial Results
    • Regulatory Status
       

Key Questions Answered in this Report

Market Insights

  • How has the Diffuse Large B-cell Lymphoma market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2021 and how are they expected to be in 2032?
  • What was the country-wise size of the Diffuse Large B-cell Lymphoma market across the seven major markets in 2021 and how will it look like in 2032?
  • What is the growth rate of the Diffuse Large B-cell Lymphoma market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the Diffuse Large B-cell Lymphoma market?

 

Epidemiology Insights

  • What is the size of the Diffuse Large B-cell Lymphoma patient pool (2017-2021) across the seven major markets?
  • What would be the forecasted patient pool (2022-2032) of Diffuse Large B-cell Lymphoma across the seven major markets?
  • What are the key factors driving the epidemiological trend of Diffuse Large B-cell Lymphoma?
  • What will be the growth rate of Diffuse Large B-cell Lymphoma patients across the seven major markets?

 

Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed Diffuse Large B-cell Lymphoma drugs and what are their market performance?
  • What are the key pipeline Diffuse Large B-cell Lymphoma drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed Diffuse Large B-cell Lymphoma drugs and what are their efficacies?
  • How safe are the late-stage pipeline Diffuse Large B-cell Lymphoma drugs and what are their efficacies?
  • What are the current treatment guidelines for Diffuse Large B-cell Lymphoma drugs across the seven major markets?
  • Who are the key companies in the Diffuse Large B-cell Lymphoma market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Diffuse Large B-cell Lymphoma market?

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Diffuse Large B-cell Lymphoma (DLBCL) - Introduction
4.1 Overview
4.2 Epidemiology (2017-2021) and Forecast (2022-2032)
4.3 Market Overview (2017-2021) and Forecast (2022-2032)
4.4 Competitive Intelligence

5 Diffuse Large B-cell Lymphoma (DLBCL) - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Diffuse Large B-cell Lymphoma (DLBCL) - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2017-2021)
7.2.2 Epidemiology Forecast (2022-2032)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2017-2021)
7.3.2 Epidemiology Forecast (2022-2032)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2017-2021)
7.4.2 Epidemiology Forecast (2022-2032)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2017-2021)
7.5.2 Epidemiology Forecast (2022-2032)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2017-2021)
7.6.2 Epidemiology Forecast (2022-2032)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2017-2021)
7.7.2 Epidemiology Forecast (2022-2032)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2017-2021)
7.8.2 Epidemiology Forecast (2022-2032)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2017-2021)
7.9.2 Epidemiology Forecast (2022-2032)

8 Diffuse Large B-cell Lymphoma (DLBCL) - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Diffuse Large B-cell Lymphoma (DLBCL) Guidelines, Management and Treatment
8.2 Diffuse Large B-cell Lymphoma (DLBCL) Treatment Algorithm

9 Diffuse Large B-cell Lymphoma (DLBCL) - Unmet Needs

10 Diffuse Large B-cell Lymphoma (DLBCL) - Key Endpoints of Treatment

11 Diffuse Large B-cell Lymphoma (DLBCL) - Marketed Products
11.1 List of Diffuse Large B-cell Lymphoma (DLBCL) Marketed Drugs Across the Top 7 Markets
11.1.1    Drug Name - Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Drug and company names have not been provided here as this is a sample TOC. Complete list to be provided in the final report.

12 Diffuse Large B-cell Lymphoma (DLBCL) - Pipeline Drugs
12.1 List of Diffuse Large B-cell Lymphoma (DLBCL) Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name - Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Drug and company names have not been provided here as this is a sample TOC. Complete list to be provided in the final report.

13. Diffuse Large B-cell Lymphoma (DLBCL) - Attribute Analysis of Key Marketed and Pipeline Drugs

14 Diffuse Large B-cell Lymphoma (DLBCL) - Market Scenario
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1    Diffuse Large B-cell Lymphoma (DLBCL) - Market Size
14.2.1.1 Market Size (2017-2021)
14.2.1.2 Market Forecast (2022-2032)
14.2.2    Diffuse Large B-cell Lymphoma (DLBCL) - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2017-2021)
14.2.2.2 Market Forecast by Therapies (2022-2032
14.3 Market Scenario - United States
14.3.1    Diffuse Large B-cell Lymphoma (DLBCL) - Market Size
14.3.1.1 Market Size (2017-2021)
14.3.1.2 Market Forecast (2022-2032)
14.3.2    Diffuse Large B-cell Lymphoma (DLBCL) - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2017-2021)
14.3.2.2 Market Forecast by Therapies (2022-2032)
14.3.3    Diffuse Large B-cell Lymphoma (DLBCL) - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1    Diffuse Large B-cell Lymphoma (DLBCL) - Market Size
14.4.1.1 Market Size (2017-2021)
14.4.1.2 Market Forecast (2022-2032)
14.4.2    Diffuse Large B-cell Lymphoma (DLBCL) - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2017-2021)
14.4.2.2 Market Forecast by Therapies (2022-2032)
14.4.3    Diffuse Large B-cell Lymphoma (DLBCL) - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1    Diffuse Large B-cell Lymphoma (DLBCL) - Market Size
14.5.1.1 Market Size (2017-2021)
14.5.1.2 Market Forecast (2022-2032)
14.5.2    Diffuse Large B-cell Lymphoma (DLBCL) - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2017-2021)
14.5.2.2 Market Forecast by Therapies (2022-2032)
14.5.3    Diffuse Large B-cell Lymphoma (DLBCL) - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1    Diffuse Large B-cell Lymphoma (DLBCL) - Market Size
14.6.1.1 Market Size (2017-2021)
14.6.1.2 Market Forecast (2022-2032)
14.6.2    Diffuse Large B-cell Lymphoma (DLBCL) - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2017-2021)
14.6.2.2 Market Forecast by Therapies (2022-2032)
14.6.3    Diffuse Large B-cell Lymphoma (DLBCL) - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1    Diffuse Large B-cell Lymphoma (DLBCL) - Market Size
14.7.1.1 Market Size (2017-2021)
14.7.1.2 Market Forecast (2022-2032)
14.7.2    Diffuse Large B-cell Lymphoma (DLBCL) - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2017-2021)
14.7.2.2 Market Forecast by Therapies (2022-2032)
14.7.3    Diffuse Large B-cell Lymphoma (DLBCL) - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1    Diffuse Large B-cell Lymphoma (DLBCL) - Market Size
14.8.1.1 Market Size (2017-2021)
14.8.1.2 Market Forecast (2022-2032)
14.8.2    Diffuse Large B-cell Lymphoma (DLBCL) - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2017-2021)
14.8.2.2 Market Forecast by Therapies (2022-2032)
14.8.3    Diffuse Large B-cell Lymphoma (DLBCL) - Access and Reimbursement Overview
14.9   Market Scenario - Japan
14.9.1    Diffuse Large B-cell Lymphoma (DLBCL)  - Market Size
14.9.1.1 Market Size (2017-2021)
14.9.1.2 Market Forecast (2022-2032)
14.9.2    Diffuse Large B-cell Lymphoma (DLBCL) - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2017-2021)
14.9.2.2 Market Forecast by Therapies (2022-2032)
14.9.3    Diffuse Large B-cell Lymphoma (DLBCL) - Access and Reimbursement Overview

15 Diffuse Large B-cell Lymphoma (DLBCL) - Recent Events and Inputs From Key Opinion Leaders

16 Diffuse Large B-cell Lymphoma (DLBCL) Market - SWOT Analysis
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats     

17 Appendix


Note: We value your privacy and will never rent or sell your email address. Privacy policy

Need more help?

  •   Speak to our experienced analysts for insights on the current market scenarios.
  •   Include additional segments and countries to customize the report as per your requirement.
  •   Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  •   For further assistance, please connect with our analysts.

Purchase Options




$ 4499

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )


Drop us an email at

sales@imarcgroup.com

Social Links

4